Recent Updates — BLCO
Bausch + Lomb Corp announced that Nathalie Bernier resigned from its Board of Directors and Science and Technology Committee, effective close of business on October 28, 2026. In connection with her departure, the company agreed to pay prorated cash compensation and fully accelerate the vesting of her unvested restricted share unit awards from the 2026 annual grant. The Board does not intend to fill the vacancy, and the resignation was not due to any disagreement regarding operations or policies. Bausch + Lomb Corp operates in the eye health care industry, manufacturing and distributing ophthalmic products.
Bausch + Lomb reported third-quarter revenue of $1.375 billion, a 7% increase from the prior year period, driven by growth across its Vision Care, Surgical, and Pharmaceuticals segments. GAAP net income was $32 million compared to a loss of $28 million in the same quarter last year, while adjusted EBITDA rose to $325 million. The company raised its full-year 2026 revenue guidance to $5.45 billion–$5.55 billion and increased adjusted EBITDA excluding acquired IPR&D guidance to $1.09 billion–$1.14 billion. Bausch + Lomb is a leading global eye health company providing contact lenses, surgical devices, and pharmaceutical products.
Bausch + Lomb Corporation announced that Chief Executive Officer Brent Saunders and the Board mutually agreed to his departure, effective October 12, 2026. Saunders will cease serving on the Board and forfeit all outstanding equity awards. In connection with the separation, he receives a lump-sum cash payment of $75.5 million plus up to $50,000 in legal fee reimbursement. Thomas J. Appio, Chairman of the Board and CEO of controlling shareholder Bausch Health Companies Inc., was appointed interim Chief Executive Officer effective immediately. The company also disclosed that it expects to raise full-year 2026 adjusted EBITDA guidance based on preliminary third-quarter results. Bausch + Lomb Corporation is a leading global eye health company developing, manufacturing, and marketing contact lenses, prescription products, surgical devices, and over-the-counter options.
Bausch + Lomb Corporation filed an amendment to report that Thomas J. Appio succeeded Brent Saunders as Chairman of the Board effective August 10, 2026, while Mr. Saunders continues serving on the board. The company also appointed Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi to its committees with specific chair roles: Dr. Paul leads the Nominating and Corporate Governance Committee, Eduardo Alfonso chairs the Science and Technology Committee, and Ms. Trebbi chairs the Talent and Compensation Committee. These changes follow earlier resignations and appointments announced on August 6, 2026. Bausch + Lomb Corporation operates in the healthcare industry, specializing in eye health products including contact lenses and ophthalmic pharmaceuticals.
Bausch + Lomb Corporation appointed four new directors—Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi—to its board effective August 5, 2026, replacing Steven H. Collis, Karen L. Ling, Thomas W. Ross, Sr., and Andrew C. von Eschenbach, M.D. The new appointments were made at the request of controlling shareholder Bausch Health Companies Inc. Resigning directors received prorated compensation and accelerated vesting of unvested restricted stock units; Mr. Ross entered a one-year consulting agreement with a $400,000 fee. The company reported second-quarter revenue of $1.394 billion, an 8% increase on a constant currency basis, and reaffirmed full-year 2026 guidance for revenue between $5.440 billion and $5.540 billion. Bausch + Lomb Corporation is a global eye health company that manufactures contact lenses, surgical devices, and pharmaceutical products.
Bausch + Lomb Corporation reported second-quarter 2026 results on July 29, 2026, with revenue of $1.394 billion, representing a 9% increase as reported and 8% on a constant currency basis compared to the prior year period. The company posted a GAAP net loss of $14 million, or ($0.04) per share, against an adjusted EBITDA of $241 million. Management raised full-year 2026 revenue guidance to $5.44 billion–$5.54 billion and adjusteded EBITDA excluding acquired IPR&D guidance to $1.025 billion–$1.075 billion, citing broad-based growth across Surgical and Pharmaceuticals segments. The company also announced positive top-line results from a pivotal clinical study for its investigational enVista Beyond intraocular lens. Bausch + Lomb operates in the eye health industry, manufacturing contact lenses, surgical devices, and pharmaceuticals.